When the Math Isn’t Mathin’: FDA’s Latest Clinical Investigator Warning Letter Highlights Why Drug Accountability Matters

FDA clinical investigator Warning Letters often involve familiar GCP themes, including protocol deviations, inadequate records, and insufficient oversight. FDA’s recent Warning Letter to a Florida clinical investigator following a Bioresearch Monitoring Program (BIMO) inspection is notable not because it breaks new regulatory ground, but because it demonstrates how routine Good Clinical Practice (GCP) deficiencies can quickly become questions of data integrity.

The July 27, 2026 Warning Letter cites two fundamental investigator responsibilities under 21 C.F.R. § 312.60 (conducting a study according to the investigational plan) and § 312.62(a) (maintaining adequate records of investigational product). While these obligations are well established, FDA’s discussion highlights how failures in either area can undermine confidence in both subject safety and the reliability of study data.

One Subject, Two Clinical Trials

FDA’s first observation involved simultaneous enrollment of a subject in two investigational drug studies. Although one protocol prohibited participation in another clinical investigation, FDA found that the subject was enrolled in a second trial while still participating in the first and received investigational product under both protocols for approximately six overlapping weeks.

Although this may appear to be a straightforward eligibility violation, the consequences extend beyond protocol compliance. Simultaneous enrollment can complicate attribution of adverse events, confound efficacy assessments, and ultimately call into question whether study data are interpretable. As sponsors increasingly rely on centralized monitoring and duplicate-subject detection tools, this Warning Letter serves as a reminder that eligibility is an ongoing responsibility, not merely a screening exercise.

When Drug Accountability Doesn’t Add Up

FDA’s second observation focused on investigational product accountability, demonstrating why FDA views drug accountability as far more than an administrative exercise.

For six subjects, FDA found discrepancies among the subjects’ dosing logs, the site’s investigational product accountability records, and the electronic data capture (EDC) system. Although the investigator explained that subjects self-administered the investigational product at home, FDA emphasized that responsibility for maintaining accurate accountability records remained with the investigator. The discrepancies became even more significant during the sponsor’s remote closeout visit. According to FDA, investigational product kits documented as dispensed and reportedly used by subjects were returned with tamper-evident seals still intact, suggesting the kits had never been opened. At that point, FDA’s concern extended beyond inconsistent paperwork to the reliability of the site’s data.

FDA also found the investigator’s corrective action response inadequate. Although the investigator noted that the study had been closed, the sponsor excluded the site’s data from its analyses, and she did not intend to conduct future clinical research, FDA concluded that the response failed to explain how similar violations would be prevented “if you should change your mind and decide to conduct clinical investigations in the future.” Even when a study has ended, FDA expects investigators to identify root causes and implement meaningful corrective and preventive actions, and a commitment not to conduct regulated research in the future is not an excuse for an inadequate plan.

Takeaways

This Warning Letter underscores several practical lessons for both sponsors and investigators.

For sponsors, eligibility verification should not rely solely on subject self-report. Where protocols prohibit concurrent trial participation, sponsors should consider risk-based approaches to detect duplicate enrollment. Likewise, home-dosing protocols require monitoring plans that reconcile subject diaries, EDC entries, accountability records, and returned investigational product throughout the study, not simply at closeout. When monitors identify discrepancies, particularly physical evidence that contradicts study records, sponsors should treat those findings as potential data integrity issues requiring prompt investigation.

For investigators, the Warning Letter is a reminder that signing the Form FDA 1572 carries responsibility for protocol compliance and investigational product accountability, regardless of where study procedures occur. Accountability records, source documentation, and EDC entries should consistently reflect what actually happened, and returned investigational product should be reconciled against those records on an ongoing basis.

More broadly, the Warning Letter illustrates that FDA evaluates GCP compliance by comparing multiple sources of evidence, not by reviewing any single record in isolation. It also serves as a reminder that corrective actions should go beyond describing what happened. Whether responding on behalf of a sponsor or an investigator, FDA expects a thoughtful root-cause analysis and concrete measures demonstrating how similar deficiencies will be prevented in future studies.